Myasthenia gravis medical therapy

	Myasthenia gravis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Myasthenia Gravis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Myasthenia gravis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Myasthenia gravis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Myasthenia gravis medical therapy
CDC on Myasthenia gravis medical therapy
Myasthenia gravis medical therapy in the news
Blogs on Myasthenia gravis medical therapy
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Myasthenia gravis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The mainstays of medical therapy for myasthenia gravis are:

An oral anticholinesterase like pyridostigmine is usually the first drug in MG patients.(5) these drugs can reduce the degradation of Ach in the synaptic cleft.(7) limbs and bulbar muscles respond very well to these drugs but ocular symptoms including diplopia are resistance to these medications.(8)